Enibomal (narcobarbital) is a barbiturate drug. By its chemical structure, it is N-methylated derivative of propallynolal. Narcobarbital was discovered in 1930s and later investigated as an anesthetic agent in gynecological surgery and electroconvulsive treatment. In the United States, narcobarbital is classified as a schedule III drug and is not found in pharmaceutical preparations. In Europe, narcobarbital was used in veterinary as a general anesthetic for pigs, but by 2000 it was withdrawn and no longer available at the market.

Oxaflozane is non-tricyclic antidepressant with serotoninergic action. In animals, oxaflozane has anti-cataleptic and anti-aggressive action with weak potentiation of stereotypes provoked by amphetamine. Oxaflozane was developed by Solvay Pharma and marketed in France under tradename Conflictan. The drug was discontinued in 2004.

Iproheptine (Metron, Susat) is a vasoconstrictor, antihistamine, nasal decongestant marketed in Japan.

Proquazon, a non-steroidal anti-inflammatory agent that was studied to use in the management of rheumatoid arthritis and osteoarthritis. The biochemical mechanism of action of proquazon via the inhibition of the core protein synthesis of proteoglycans and the secondary biosynthesis of the glucosamine.

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Azelnidipine (INN; marketed under the brand name CalBlock) is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for both L-type and T-type Ca channels. It has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that long-term treatment with azelnidipine effectively controls blood pressure (BP) in a cohort of 95 patients with mild-to-moderate hypertension. The antihypertensive efficacy of azelnidipine in patients with mild-to-moderate hypertension was shown to be similar to that of amlodipine or nitrendipine in a randomised double-blind study. Azelnidipine and amlodipine controlled 24-hour BP to a similar extent. Azelnidipine is generally well tolerated. Vasodilator adverse events such as headache and hot facial flushes account for most of the adverse events. Its use is not associated with reflex tachycardia.

Ecabet is an anti-ulcer agent, marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis. Ecabet eradicates Helicobacter pylori infection in gastric ulcer patients. Antibacterial effect of ecabet is demonstrated at low pH, is mediated by inhibition of bacterial urease and accompanied by interference with TLR4 signaling and pepsin inhibition. Ecabet is also investigated for the treatment of dry eye syndrome.

Isoaminile is a cough suppressant that acts by influencing the cough centre.

Abecarnil (isopropyl 6-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate) is a nonselective mixed full agonist/partial agonist at GABA(A) receptor subtypes. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil has been studied in the treatment of anxiety disorders however its development has been discontinued.